Jiangbo Pharmaceuticals Inc

Jiangbo Pharmaceuticals — Investor Presentation (May 2010)

27 slides from Jiangbo Pharmaceuticals's investor presentation, May 20, 2010

  1. Slide 1: Jiangbo Pharmaceuticals, Inc. Corporate Presentation

    Slide 1: Jiangbo Pharmaceuticals, Inc. Corporate Presentation

    Exhibit 99.2 yo Wigs Jiangbo Pharmaceuticals, Inc. Corporate Presentation May 2010

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement ee ———S This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual r

  3. Slide 3: Reasons to Invest

    Slide 3: Reasons to Invest

    Reasons to Invest ) Attractive valuation and strong financial position Extensive sales network Government support for extending healthcare benefits Growth opportunities through acquisitions of pharmaceutical companies or new drugs

  4. Slide 4: Equity Snapshot

    Slide 4: Equity Snapshot

    Equity Snapshot Ss Jiangbo researches, develops, produces, markets and sells Western and Chinese Traditional Chinese Medicines (TCMs) in the form of tablets, time-release capsules, granules, syrups and electuaries (sticky syrup) Stock Symbol: JGBO.OB Price (05/13/10): $8.25 Market Cap: $95.0 Million

  5. Slide 5: Investment Highlights

    Slide 5: Investment Highlights

    Investment Highlights Pr ee 2. e Portfolio of sophisticated branded drugs « 4 Western chemical drugs and 13 Traditional Chinese Medicines « 17 approved TCM's waiting for launch « Jiangbo branded products are popular among consumers e Extensive distribution with scalable growth « Using 26 independent

  6. Slide 6: Market Growth Drivers

    Slide 6: Market Growth Drivers

    Market Growth Drivers aaBn ————EEEE * China, currently the world’s sixth-largest pharmaceutical market, will account for 21% of global sales growth in the pharmaceutical industry through 2013, with projected average annual growth of 40% through 2011. * * By 2011, China should become the third-bigges

  7. Slide 7: Company History

    Slide 7: Company History

    Company History S fm + 2009: December — Obtained renewal of GMP certificate for its main manufacturing factory + 2009: April — Company name changed to Jiangbo Pharmaceuticals, Inc. (OTCBB: JGBO) + 2009: February — Completed acquisition of Hongrui Pharmaceuticals’ physical assets and the rights to ma

  8. Slide 8: Modern Facilities

    Slide 8: Modern Facilities

    Modern Facilities Teas Operations in Laiyang City, Yantai, Shandong Province, PRC 10,900 square meters of production, office, and storage space 1,535 employees - including 425 production crew, 110 administrators, 440 full-time salespeople and 560 part-time salespeople | Annual production capacity in

  9. Slide 9: Accredited Production

    Slide 9: Accredited Production

    Accredited Production SE « Has certificates of Good Manufacturing Practices for Pharmaceutical Products (an international standard) from the Shandong State Drug Administration A Ae at HA A UE SEA BL AWRGMPIER Sein emia

  10. Slide 10: Production Process

    Slide 10: Production Process

    Production Process 4

  11. Slide 11: Well Established Brand Name

    Slide 11: Well Established Brand Name

    Well Established Brand Name ) RHSRRER Clarithromycin sustained- _Itopride Hydrochloride Baobaole chewable Radix Isatidis release tablet granules tablet Dispersible Tablets - Kang Gu Sui Yan Pian (an Laiyang Pear Cough Syrup osteomyelitis treatment tablet) ae Bec Yi Mu Cao Gao (a motherwort herb elec

  12. Slide 12: Product Portfolio

    Slide 12: Product Portfolio

    po) Product Portfolio ame ~~ ie ~ Clarithromycin 39.9% Infections such as pneumonia, Top 2 manufacturer in bronchitis and infections of the ears, sustained-released a China sinuses, skin, and throat tablets Itopride Hydrochloride 26.2% Gastro-intestinal system related Top 8 manufacturer in granules

  13. Slide 13: Hongrui TCM Products

    Slide 13: Hongrui TCM Products

    Hongrui TCM Products en In early 2009, Jiangbo purchased the rights to manufacture and distribute 22 TCMs 14 products selected for production during the first phase Laiyang Pear Lalyang Pear syrup and pulps to contro! coughs 1) Lalyang Pear Cough Syrup series arising from various factors Osteomyelit

  14. Slide 14: R&D and Product Pipeline

    Slide 14: R&D and Product Pipeline

    R&D and Product Pipeline Jiangbo has built close relationships with several well known Chinese R&D institutions + The Institute of Microbiology, Chinese Academy of Sciences + Pharmaceutical institute of Shandong University + Shandong Chinese Traditional Medicine Technical School Collaboration with R

  15. Slide 15: Extensive Distribution Network / Marketing and Advertising

    Slide 15: Extensive Distribution Network / Marketing and Advertising

    Extensive Distribution Network / © Marketing and Adverti ng LH - Cover all of China except for Ningxia - Sell to hospitals and pharmacies mostly through 26 first tier distributors . Internal sales team of 1000 persons - Organize cooperative promotional activities with distributors . Advertise Over T

  16. Slide 16: Management Team

    Slide 16: Management Team

    Management Team ems lm —=E Wubo Cao, Chief Executive Officer and Chairman Chairman and General Manager of Laiyang Jiangbo Pharmaceutical Co. Ltd. since 2003 Experienced in founding and managing drug manufacturing companies Has over 20 years of work experience in Chinese pharmaceutical industry Elsa

  17. Slide 17: Business Strategy

    Slide 17: Business Strategy

    Business Strategy S Continue to source and develop sophisticated drugs that meet certification and patent standards and have long product life spans Leverage the distribution network to deepen and expand distribution to existing markets and underserved rural markets in coordination with government p

  18. Slide 18: Financial Highlights

    Slide 18: Financial Highlights

    S Wigs] Jiangbo Pharmaceuticals, Inc. Financial Highlights

  19. Slide 19: Strong Revenue Growth

    Slide 19: Strong Revenue Growth

    Strong rl Line Growth.-- S i CAGR=24.1% 80 74 a 96 -98 762 40 20 0 FY2007 Fy2008 Fy2009 FY2010E (Fiscal Year Ends June 20) 2010 estimated revenue reflects new company strategy beginning in January 2009 to charge lower unit prices to its 26 independent distributors to shift marketing expenses to dist

  20. Slide 20: Financial Growth from Key Drugs

    Slide 20: Financial Growth from Key Drugs

    Financial Growth from Key Drugs S eee Revenue Breakdown by Drug FY2007 FY2008 FY2009 9 mo FY2010" 1 Others 1 Kopride Hydrochloride granules 0 Carithromycin sustained-release tablets 1 Baobaole chewable tablets 1 Radix Isatidis Dispersible Tablets, * For the nine months ended March 31, 2010 me

  21. Slide 21: Gross Profit and Gross Margin

    Slide 21: Gross Profit and Gross Margin

    FY2007 FY2008 FY2009 FY2010E Gi Gross Profit —@Gross Margin 2009 revenue reflects new company strategy beginning in January 2009 to charge lower unit prices to its 28 independent distributors to shift marketing expenses to distributors. 20108 is estimated based on reported gross margin for the nine

  22. Slide 22: Income From Operations

    Slide 22: Income From Operations

    Income From Operations== a we 607 re + 50% 5 42.4% : = + 40% ¢ 32.4% 40 42-44 30% 24.0% 30+ 32.2 20% 20+ ‘| | ' Oo 0% FY2007 FY2008 FY200E [a Income From Operations —@— Operating Margin 22

  23. Slide 23: Net Income

    Slide 23: Net Income

    Net Income FY2007 FY2008 FY2009 9 mo FY2010* a Net Income Net Margin * For the nine months ended March 31, 2010 23

  24. Slide 24: Summary Income Statement ($ in millions)

    Slide 24: Summary Income Statement ($ in millions)

    ($ in millions) For Twelve Months Ended For Nine Months Period June 30 Ended March 31 “2007, =—=s—=i«200s—tti« 2009 “20092010 Total Sales Revenue 76.2 99.5 117.4 86.2 68.1 Gross Margin 72.2% 114% 76.2% TIA% 73.7% SGA Expenses 25.6 41.6 35.3 314 13.4 Operating Margin 24.0% 32.4% 42.4% 37.2% 49.2% Net

  25. Slide 25: Balance Sheet ($ in thousands)

    Slide 25: Balance Sheet ($ in thousands)

    t ($ in thousands) Working Capital Cash Accounts Receivable, Net of Allowance Inventories Total Current Assets Total Assets Total Current Liabilities Total Liabilities Retained Earnings Total Shareholders' Equity June 30, 2008 73,156 48,196 24,312 3,906 89,534 114,395 16,378 18,878 39,008 95,516 Jun

  26. Slide 26: Investment Summary

    Slide 26: Investment Summary

    Investment Summary S Attractive valuation and strong financial position Extensive sales network Government support for extending healthcare benefits Growth opportunities through acquisitions of pharmaceutical companies or new drugs

  27. Slide 27: Contacts

    Slide 27: Contacts

    Contacts oO) Se Jiangbo Pharmaceuticals, Inc. Ms Elsa Sung, CFO Phone: (954) 903-9378 ex 2 Email: elsasung@jiangbo.com http:/Awww.jiangbopharma.com/ CCG Investor Relations, Inc. Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com http:/Awww.ccgir.com/ 27

Source: SEC EDGAR · 8-K filed May 20, 2010